Beactica has expanded its collaboration with Boehringer Ingelheim under which Beactica will use its fragment-based platform to identify novel and selective hits against oncology-relevant kinases of interest to Boehringer. Financial terms were not disclosed.
"We are pleased to expand our work with Boehringer Ingelheim and look forward to further supporting them in their discovery of innovative, new medicines for the treatment of cancer," said Beactica chief executive officer, Dr. Per Källblad. "The collaboration builds on Beactica's strategy of establishing long-term relationships with leading pharmaceutical companies and validates the potential of our drug discovery platform."
The companies originally entered an alliance in 2008 involving the interaction mechanism of Giotrif (afatinib), a treatment that has been recently approved for lung cancer patients with EGFR mutations in Europe and the U.S.
Beactica, Boehringer Expand Drug Discovery Alliance
Published October 22, 2013
blog comments powered by Disqus